Location History:
- Flint, MI (US) (1992 - 1994)
- Portage, MI (US) (2004 - 2006)
- Notre Dame, IN (US) (2015)
- St. Louis, MO (US) (2019)
- South Bend, IN (US) (2019 - 2023)
- Granger, IN (US) (2007 - 2024)
Company Filing History:
17 out of 368 
9 out of 579 
2 out of 1,584 
Years Active: 1992-2024
Title: Innovations in Antibiotics by Shahriar Mobashery
Introduction
Shahriar Mobashery, based in Granger, Indiana, is a prolific inventor with an impressive portfolio of 22 patents. His work primarily focuses on groundbreaking compounds aimed at treating bacterial infections, particularly those that pose significant public health threats.
Latest Patents
Among his latest innovations, Mobashery has developed compounds specifically targeting Clostridium difficile infection (CDI), which is responsible for approximately 14,000 deaths annually in the United States. The challenge with CDI lies in the resilience of its spores, which can remain dormant for years, alongside the production of harmful toxins. Current treatments such as vancomycin and metronidazole often fail to prevent spore formation and toxin production, leading to a recurrence rate of 25% in patients. Mobashery's research introduces oxadiazoles capable of combatting the virulent NAP1/027 strain, known for producing increased levels of toxins A and B. Notably, one of these compounds, Oxadiazole 2, is designed to remain poorly absorbed, allowing it to reach high concentrations in the gut, effectively targeting peptidoglycan synthesis, inhibiting vegetative cells, spores, and toxin production. Additionally, he has also disclosed innovative antibacterial drug combinations aimed at addressing infections caused by antibiotic-resistant bacteria.
Career Highlights
Mobashery's academic journey includes significant tenures at esteemed institutions, notably the University of Notre Dame and Wayne State University. His extensive research in the field of microbiology and chemistry has led to numerous advancements in antibiotic therapy.
Collaborations
In his quest for innovation, Mobashery has built productive collaborations with notable colleagues, including Mayland Chang and Mijoon Lee. These partnerships have played a critical role in shaping his research endeavors and enhancing the reach of his inventions.
Conclusion
Shahriar Mobashery stands out as a key figure in the fight against bacterial infections through his innovative approaches and inventions. His latest patents represent a significant step toward more effective treatments for CDI and antibiotic-resistant infections, showcasing his commitment to addressing critical healthcare challenges.